Peter Lawætz Andersen, Vice President

Peter Lawætz Andersen
DVM, DMSc, Professor
Statens Serum Institut
5 Artillerivej , 81/301
DK-2300 Copenhagen S
+45 3268 3268

Research area

Peter L. Andersen is Vice President of Vaccine R&D at Statens Serum Institut and Adjunct Professor in Immunology at Copenhagen University. His research has been focused on the identification and characterisation of antigens, immune mechanisms and vaccine delivery systems that mediate protection against important pathogens such as Mycobacterium tuberculosis, Chlamydia trachomatis and Influenza. He has pioneered work on TB vaccines, the CAF series of liposomal adjuvants and novel TB diagnostic assays and reagents.

In his current position, he is responsible for the overall coordination of vaccine research and development covering activities from early research to clinical development. This program currently has 3 different TB vaccines, a novel liposomal adjuvant formulation and a new TB skin test under clinical testing, and a number of experimental vaccines in the late preclinical stage. In collaboration with industrial partners his team has furthermore developed novel TB diagnostic tests (the IGRA assays), that are in widespread worldwide clinical use today. Professor Andersen has an extensive scientific production of more than 270 papers (current H-index 68) and 20 patents. He has organized and chaired many international meetings, given lectures all over the world and received numerous large national and international research grants. Peter L. Andersen heads several international research consortiums, and from 1990 to 2005 he was the most cited researcher in Denmark within the field of immunology. Also he is one of the most cited researchers in the world within tuberculosis. He has received many prizes and awards and in 2011 he received the Novo Nordisk Prize; the most prestigious Danish award given as an acknowledgement of a lifetime scientific achievement.

Selected publications

  • Lindenstrom T, Knudsen NP, Agger EM, Andersen P. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. Journal of immunology. 2013;190(12):6311-9.
  • Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Andersen P et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. The Journal of clinical investigation. 2012;122(1):303-14.
  • Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Andersen P et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nature medicine. 2011;17(2):189-94.
  • Kaufmann SHE, Andersen P. Immune intervention strategies against tuberculosis. In: Kaufmann SHE, Rouse BT, Sacks DL, editors. The Immune Response to Infection. Washington, D.C.: ASM Pr.; 2011. p. 571 - 86.